文献速递细菌感染、耐药与抗菌药物结核与非结核分枝杆菌

脓肿分枝杆菌肺病患者氨基糖苷类治疗中获得性阿米卡星耐药机制与选择

Deciphering acquired resistance to amikacin in Mycobacterium abscessus clinical isolates selected from patients with pulmonary disease treated with aminoglycoside: a 2012-2025 retrospective cohort study.
PubMed 文献 · Clin Microbiol Infect · 2026-09-25

该回顾性队列纳入2012—2025年参考中心收治的脓肿分枝杆菌肺病患者,选取至少分离到1株阿米卡星耐药株者。30例患者共113株菌(73株耐药、40株敏感)分析显示,耐药主要与rrs A1408G突变相关,也存在其他rrs位点及whiB7上游缺失;纵向随访提示耐药可在氨基糖苷类治疗下从敏感群体中被选择,且停药后仍可持续存在。

要点

  • 阿米卡星耐药以rrs A1408G突变为主,但其他rrs位点及whiB7上游缺失也可见。
  • 耐药可在静脉、雾化或脂质体吸入氨基糖苷类治疗过程中被选择出现。
  • 部分患者停用氨基糖苷类后耐药株仍持续存在,需基因组学排查。

核心结论

  • 脓肿分枝杆菌肺病患者在氨基糖苷类治疗下可获得阿米卡星耐药,主要机制为rrs A1408G突变,并存在其他rrs位点突变及whiB7上游缺失等机制。

研究设计与样本

  • 2012—2025年单参考中心回顾性队列,从727例患者893株脓肿分枝杆菌中选取30例至少1株阿米卡星耐药株的患者,共分析113株菌(73株耐药、40株敏感),并行全基因组测序。

主要发现

  • 30例中28例为囊性纤维化患者,29例曾接受阿米卡星和/或妥布霉素(静脉和/或雾化)和/或阿米卡星脂质体吸入混悬液。
  • rrs A1408G见于30例中的24例,另见C1409T(1例)、G1491T(2例)及新发C1496T(2例),1例检出whiB7上游缺失。
  • 16例敏感/耐药配对纵向随访显示耐药出现与氨基糖苷类品种或给药途径无关;16例中13例停药后耐药株仍存在。
  • 患者内敏感/耐药配对菌株中位SNP差异为5(IQR 3–11),支持耐药突变在体内从敏感群体中被选择。

关键数值与推荐

  • 阿米卡星耐药定义为肉汤微量稀释法MIC>64 mg/L(依据EUCAST流行病学折点)。

临床怎么用

  • 对氨基糖苷类治疗中的脓肿分枝杆菌肺病患者应监测阿米卡星耐药,耐药机制不限于A1408G,宜结合基因组检测判读。
  • 耐药株可在停药后持续存在,提示不能仅凭停药推断耐药消失。

局限性

  • 为单中心回顾性研究,样本量有限(30例患者、113株菌),多数为囊性纤维化患者,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Amikacin (AMK) is one of the most active antimicrobials for treating Mycobacterium abscessus pulmonary disease (MAB-PD). Acquired AMK resistance (AMK-R) was described with an A1408G mutation in rrs encoding the 16S ribosomal RNA. Clinical frequency of other mutations remains unknown. This study aims to decipher AMK-R mechanisms and selection in patients with MAB-PD. METHODS: From 2012 to 2025, we included all MAB isolates sent to our reference centre from patients with MAB-PD and selected the patients for whom at least one AMK-R isolate was obtained (Minimum Inhibitory Concentration determined by broth microdilution >64 mg/L according to the European Committee on Antimicrobial Susceptibility Testing epidemiological cut-off value). We collected patient data, including aminoglycoside intake. Whole genome sequencing was performed on sequential AMK-R and AMK-susceptible (AMK-S) isolates. RESULTS: Among 893 MAB isolates from 727 patients, 113 from 30 patients were included in this study (73 AMK-R and 40 AMK-S). Most isolates were from patients with cystic fibrosis (28 of 30) who had received AMK and/or tobramycin (TOB), intravenous (IV) and/or inhaled, and/or AMK liposomal inhaled suspension (29 of 30). The A1408G rrs mutation was found in 24 of 30 patients. Other rrs mutations were also found, such as C1409T (one patient), G1491T (two patients), and a novel C1496T in two patients. A deletion upstream whiB7, a gene associated with multidrug resistance, was also identified for one patient. Longitudinal follow-up of 16 patients with AMK-S/R couples highlighted the emergence of AMK-R, regardless of the aminoglycoside molecule or the administration route. AMK-R isolates remained in 13 of 16 patients independently of aminoglycoside discontinuation. Intrapatient AMK-S/AMK-R couples differed only by a median (interquartile range [IQR]) of 5 (3-11) single-nucleotide polymorphisms, confirming the in vivo selection of AMK-R mutants from the AMK-S population. CONCLUSIONS: In patients with MAB-PD, AMK-R can be selected under aminoglycoside treatment, mainly through an A1408G rrs mutation, but also with mutations at other rrs loci or in other genes, requiring a genomic investigation.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Allam C, Agsous S, Søndermøle M, et al. Deciphering acquired resistance to amikacin in Mycobacterium abscessus clinical isolates selected from patients with pulmonary disease treated with aminoglycoside: a 2012-2025 retrospective cohort study. Clin Microbiol Infect. 2026. PMID: 42790778. doi:10.1016/j.cmi.2026.09.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。